UR9 Stock Overview A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Clinuvel Pharmaceuticals Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Clinuvel Pharmaceuticals Historical stock prices Current Share Price AU$7.36 52 Week High AU$10.65 52 Week Low AU$7.32 Beta 0.86 1 Month Change -9.37% 3 Month Change -18.46% 1 Year Change -24.95% 3 Year Change -58.69% 5 Year Change -58.33% Change since IPO 41.44%
Recent News & Updates
CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP Oct 01
Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024 Sep 13
Dividend of AU$0.05 announced Sep 01
Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023) Aug 29
Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 19
New minor risk - Share price stability Jul 26 See more updates
CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP Oct 01
Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024 Sep 13
Dividend of AU$0.05 announced Sep 01
Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023) Aug 29
Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 19
New minor risk - Share price stability Jul 26
Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary Jun 28
CLINUVEL Announces A Novel Clinical Program Jun 19
Investor sentiment improves as stock rises 15% Mar 18
First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023) Feb 23
Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024 Feb 16
Clinuvel Pharmaceuticals Limited Announces Board Changes Sep 29
Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023 Sep 13
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023 Aug 30
Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022) Aug 29
Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023 Aug 28
Investor sentiment deteriorates as stock falls 15% Mar 02
First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022) Feb 25
Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant Feb 15
Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation Feb 02
Now 21% undervalued Feb 02
Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance Jan 23
Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum Jan 17
Now 23% undervalued Jan 11
Investor sentiment improved over the past week Jan 10
No independent directors Nov 16
Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104 Oct 20
Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022 Sep 08
Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021) Aug 31
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022 Aug 30
Now 22% undervalued Aug 13
Investor sentiment improved over the past week Aug 01
CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803) Jul 28
Investor sentiment improved over the past week Jul 10
Investor sentiment improved over the past week Jun 25
Non-Executive Director recently sold €240k worth of stock Jun 15 CLINUVEL Progresses CUV104 Vitiligo Study May 10
CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke May 05
No independent directors Apr 27
Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director Apr 04
Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study Mar 30
CEO, MD & Director recently sold €764k worth of stock Mar 24
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 25
Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study Jan 18
Investor sentiment deteriorated over the past week Nov 09
Investor sentiment improved over the past week Sep 02
Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020) Aug 27
CEO, MD & Director recently sold €2.4m worth of stock Jul 07
Non-Executive Director recently sold €439k worth of stock Jul 01
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide Jun 08
CEO, MD & Director recently sold €2.0m worth of stock Jun 04
CEO, MD & Director recently sold €1.7m worth of stock Mar 06
Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021 Mar 04
Investor sentiment improved over the past week Mar 03
New 90-day high: €14.89 Mar 02
First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020) Feb 25
Revenue misses expectations Feb 25
Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021 Feb 21
New 90-day low: €12.10 Nov 02
Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program Sep 15
New 90-day low - €12.50 Aug 30
Full year earnings released Aug 28 Shareholder Returns UR9 DE Biotechs DE Market 7D -2.8% -1.0% -1.1% 1Y -24.9% -12.8% 8.1%
See full shareholder returns
Return vs Market: UR9 underperformed the German Market which returned 9.2% over the past year.
Price Volatility Is UR9's price volatile compared to industry and market? UR9 volatility UR9 Average Weekly Movement 3.8% Biotechs Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: UR9 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: UR9's weekly volatility (4%) has been stable over the past year.
About the Company Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Show more Clinuvel Pharmaceuticals Limited Fundamentals Summary How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap? UR9 fundamental statistics Market cap €368.58m Earnings (TTM ) €21.50m Revenue (TTM ) €53.21m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) UR9 income statement (TTM ) Revenue AU$88.18m Cost of Revenue AU$7.73m Gross Profit AU$80.45m Other Expenses AU$44.81m Earnings AU$35.64m
Dividends
0.4% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/17 04:16 End of Day Share Price 2024/12/17 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Thomas Wakim Bell Potter Norbert Kalliwoda Dr. Kalliwoda Research David Stanton Jefferies LLC
Show 7 more analysts 
